

## Brilliant Violet 605™ anti-human CD4 Antibody

<b>Catalog# / Size</b>	317437 / 25 tests 317438 / 100 tests
<b>Clone</b>	OKT4
<b>Regulatory Status</b>	RUO
<b>Workshop</b>	HCDM listed
<b>Other Names</b>	T4
<b>Isotype</b>	Mouse IgG2b, κ
<b>Description</b>	CD4, also known as T4, is a 55 kD single-chain type I transmembrane glycoprotein expressed on most thymocytes, a subset of T cells, and monocytes/macrophages. CD4, a member of the Ig superfamily, recognizes antigens associated with MHC class II molecules and participates in cell-cell interactions, thymic differentiation, and signal transduction. CD4 acts as a primary receptor for HIV, binding to HIV gp120. CD4 has also been shown to interact with IL-16.

### Product Details

---

<b>Verified Reactivity</b>	Human, Cynomolgus, Rhesus
<b>Reported Reactivity</b>	Chimpanzee
<b>Antibody Type</b>	Monoclonal
<b>Host Species</b>	Mouse
<b>Immunogen</b>	Human peripheral T cells
<b>Formulation</b>	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
<b>Preparation</b>	The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 605™ under optimal conditions.
<b>Concentration</b>	Lot-specific (to obtain lot-specific concentration, please enter the lot number in our <a href="#">Concentration and Expiration Lookup</a> or <a href="#">Certificate of Analysis</a> online tools.)
<b>Storage &amp; Handling</b>	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. <b>Do not freeze.</b>
<b>Application</b>	<a href="#">FC - Quality tested</a>
<b>Recommended Usage</b>	<p>Each lot of this antibody is quality control tested by <a href="#">immunofluorescent staining with flow cytometric analysis</a>. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.</p> <p>Brilliant Violet 605™ excites at 405 nm and emits at 603 nm. The bandpass filter 610/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. <b>Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel.</b> Refer to your instrument manual or manufacturer for support. Brilliant Violet 605™ is a trademark of Sirigen Group Ltd.</p> <p><a href="#">Learn more about Brilliant Violet™.</a></p> <p>This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.</p>
<b>Excitation Laser</b>	Violet Laser (405 nm)
<b>Application Notes</b>	The OKT4 antibody binds to the D3 domain of CD4 and does not block HIV binding. Additional

reported applications (for the relevant formats) include: immunohistochemistry of frozen sections and blocking of T cell activation. This clone was tested in-house and does not work on formalin fixed paraffin-embedded (FFPE) tissue. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/μg, Azide-Free, 0.2 μm filtered) is recommended for functional assays (Cat. No. 317453 and 317454).

In a small subset of individuals, the OKT4 clone does not bind to CD4 due to polymorphisms in CD4.<sup>9</sup>

## Application References

1. Knapp W, *et al.* 1989. Leucocyte Typing IV. Oxford University Press. New York.
2. Reinherz EL, *et al.* 1979. *Proc. Natl. Acad. Sci.* 76:4061.
3. Kmiecik M, *et al.* 2009. *J. Transl. Med.* 7:89. (FC) [PubMed](#)
4. Cicin-Sain L, *et al.* 2010. *J. Immunol.* 184:6739. [PubMed](#)
5. Rosenzweig M, *et al.* 2001. *J. Med. Primatol.* 30:36.
6. Linder J, *et al.* 1987. *Am. J. Pathol.* 127:1.
7. Boche D, *et al.* 1999. *J. Neurovirol.* 5:232. (IHC)
8. Reinherz EL, *et al.* 1979. *Proc. Natl. Acad. Sci. USA.* 76:4061. (Immunogen)
9. Lederman S, *et al.* 1991. *Mol Immunol.* 28:1171-81.

## Product Citations

1. Gao R, *et al.* 2021. *iScience.* 24:103133. [PubMed](#)
2. Tatari N, *et al.* 2022. *Front Immunol.* 13:905768. [PubMed](#)
3. Freeman ZT, *et al.* 2020. *J Clin Invest.* 130:1405. [PubMed](#)
4. Le Q, *et al.* 2021. *Clin Cancer Res.* Online ahead of prin. [PubMed](#)
5. Arunachalam PS, *et al.* 2021. *Nature.* 596:410. [PubMed](#)
6. Groß R, *et al.* 2022. *EBioMedicine.* 75:103761. [PubMed](#)
7. Liao JB, *et al.* 2021. *J Immunother Cancer.* 9: [PubMed](#)
8. Bialas K, *et al.* 2015. *Proc Natl Acad Sci U S A.* 112: 13645 - 13650. [PubMed](#)
9. Colleen S McGary *et al.* 2017. *Immunity.* 47(4):776-788 . [PubMed](#)
10. Blandine Monel *et al.* 2019. *Cell reports.* 27(1):142-153 . [PubMed](#)
11. Iwabuchi R, *et al.* 2021. *Frontiers in Immunology.* 12:643040. [PubMed](#)
12. Caduff N, *et al.* 2021. *Cell Reports.* 35(5):109056. [PubMed](#)
13. Smedley J, *et al.* 2016. *PLoS One.* 11: 0157535. [PubMed](#)
14. Serra EG, *et al.* 2020. *Nat Commun.* 11:995. [PubMed](#)
15. Berezhnoy A, *et al.* 2020. *Cell Rep Med.* 1:100163. [PubMed](#)
16. Farhadian SF, *et al.* 2022. *JCI Insight.* 7: [PubMed](#)
17. Ellis GI, *et al.* 2022. *STAR Protoc.* 3:101784. [PubMed](#)
18. Cohen CA, *et al.* 2021. *Nat Commun.* 12:4678. [PubMed](#)
19. Rossignol ED, *et al.* 2021. *Cell Reports.* 35(8):109167. [PubMed](#)
20. Iwamoto N, *et al.* 2021. *PLoS One.* 16:e0248973. [PubMed](#)
21. Hensley-McBain T, *et al.* 2016. *J Virol.* 90: 4981 - 4989. [PubMed](#)
22. Gannon PO, *et al.* 2020. *Cytotherapy.* 22(12):780-791. [PubMed](#)
23. Waight JD, *et al.* 2018. *Cancer Cell.* 33:1033. [PubMed](#)
24. Om K, *et al.* 2020. *PLoS Pathog.* 16:e1008764. [PubMed](#)
25. Pi J, *et al.* 2022. *J Nanobiotechnology.* 20:36. [PubMed](#)
26. Stone D, *et al.* 2021. *Hum Gene Ther.* 32:96. [PubMed](#)
27. Zhang H *et al.* 2018. *Cell.* 175(5):1244-1258 . [PubMed](#)
28. Hackstein CP, *et al.* 2022. *Nat Commun.* 13:7472. [PubMed](#)
29. Wang Y, *et al.* 2021. *Cell Reports.* 36(6):109516. [PubMed](#)
30. Misheva M, *et al.* 2022. *Nat Commun.* 13:139. [PubMed](#)
31. Nath AS, *et al.* 2022. *Cell Rep.* 38:110433. [PubMed](#)
32. Walker-Sperling VE *et al.* 2017. *EBioMedicine.* 16:141-149 . [PubMed](#)

## RRID

AB\_11204077 (BioLegend Cat. No. 317437)  
AB\_11218995 (BioLegend Cat. No. 317438)

## Antigen Details

---

<b>Structure</b>	Ig superfamily, type I transmembrane glycoprotein, 55 kD
<b>Distribution</b>	T cell subset, majority of thymocytes, monocytes/macrophages
<b>Function</b>	MHC class II co-receptor, lymphocyte adhesion, thymic differentiation, HIV receptor
<b>Ligand/Receptor</b>	MHC class II molecules, HIV gp120, IL-16
<b>Cell Type</b>	Macrophages, Monocytes, T cells, Thymocytes, Tregs
<b>Biology Area</b>	Immunology
<b>Molecular Family</b>	CD Molecules
<b>Antigen References</b>	1. Center D, <i>et al.</i> 1996. <i>Immunol. Today</i> 17:476. 2. Gaubin M, <i>et al.</i> 1996. <i>Eur. J. Clin. Chem. Clin. Biochem.</i> 34:723.
<b>Gene ID</b>	<a href="#">920</a>

## Related Protocols

---

[Cell Surface Flow Cytometry Staining Protocol](#)


## Other Formats

---

Brilliant Violet 650™ anti-human CD4, Purified anti-human CD4, Biotin anti-human CD4, FITC anti-human CD4, PE anti-human CD4, PE/Cyanine5 anti-human CD4, PE/Cyanine7 anti-human CD4, APC anti-human CD4, APC/Cyanine7 anti-human CD4, Alexa Fluor® 488 anti-human CD4, Alexa Fluor® 647 anti-human CD4, Alexa Fluor® 700 anti-human CD4, Pacific Blue™ anti-human CD4, PerCP/Cyanine5.5 anti-human CD4, PerCP anti-human CD4, Brilliant Violet 421™ anti-human CD4, Brilliant Violet 605™ anti-human CD4, Brilliant Violet 711™ anti-human CD4, Brilliant Violet 785™ anti-human CD4, Brilliant Violet 510™ anti-human CD4, Brilliant Violet 570™ anti-human CD4, PE/Dazzle™ 594 anti-human CD4, TotalSeq™-A0922 anti-human CD4, Ultra-LEAF™ Purified anti-human CD4

## Product Data

---



Human peripheral lymphocytes were stained with CD4 (clone OKT4) Brilliant Violet 605™.

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

\*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, [www.biolegend.com/ordering#license](http://www.biolegend.com/ordering#license)). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 [www.biolegend.com](http://www.biolegend.com)  
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587